AdminiStar okays billing patients for difference for prostate cancer drugs

Why This Topic Matters

The policy can affect whether a practice is paid at the higher drug cost, whether a patient may be billed for a difference in amount, and what documentation is needed to support claims. It is important for avoiding denials and aligning coding and billing with the applicable Medicare coverage guidance.

Article Sections

1. AdminiStar LCD and reimbursement policy

   Summarizes the coverage decision and the general Medicare payment approach discussed in the article. It also introduces the affected therapeutic category and the overall billing implications.

2. Patient billing, ABN, and documentation requirements

   Covers the conditions described for patient liability, advance notice, and supporting records. It also notes the article’s discussion of exceptions and claim documentation.

3. Codes for LH-RH administration

   Lists the procedure and drug reporting identifiers associated with the therapies discussed. The section connects the services to the diagnosis referenced in the article.

4. Avoid denials

   Addresses coverage limitations, quantity and frequency concerns, and the kinds of documentation the article says may be requested. It focuses on circumstances described as potential denial triggers.

5. Coding tips

   Provides broad guidance on the reporting of specific formulations and implant procedures. The section organizes the article’s drug and device coding notes by product type and duration of treatment.